The father of five children had won a toy at a raffle.
He called his kids together to ask which one should have the present.
"Who is the most obedient?" he asked. "Who never talks back to mother? Who does everything she says?"
Five small voices answered in unison. "Okay, dad, you get the toy."
L-DopaIn 1970, L-dopa (levo-dihydroxyphenylalanine) was reported to benefit about 5% of the patients in reversing the progress of Parkinson's disease. The results of the first widescale experimental use of the drug were announced at a symposium on L-dopa at Georgetown University School of Medicine by Dr. Robert Keen, director of clinical pharmacology for Eaton Laboratories. The work also showed partial improvement in 56% of the 601 patients in this testing, which preceded approval by the U.S. Food and Drug Agency. However, side effects were found to be widespread, ranging from nausea, vomiting or appetite loss to confusion, nervousness or hallucinations. Preliminary investigations three years earlier showed the potential for the drug, when no other effective drug existed.* L-dopa entered national distribution in Sep 1970.« [Image: L-dopa molecule.] |
